Net revenues for the quarter were $224 million, representing a 2% increase over net revenues of $220 million for the same quarter last year. On a constant currency basis revenue grew by 3.1%. Year-to-date, net revenues were $443 million, representing a 1% increase over the same period last year.
ICON today announced the official opening of a purpose-built clinical pharmacology unit within the Central Manchester University Hospitals Foundation Trust (CMFT) campus in Manchester, UK. Initial studies in the unit utilising translational medicine methodologies to expedite drug development projects began in June, and already 110 volunteers have participated in studies there
today announced the appointment of Jonathan M Fishbein, M.D. as Vice President and Global Head for the Infectious Disease & Vaccines Therapeutic Area Group at ICON Clinical Research. Dr. Fishbein, who has extensive experience in the planning and execution of clinical research in a broad range of therapeutic areas, will oversee the growth and management of the infectious disease portfolio
Dublin, Ireland, 30th June 2010: ICON Central Laboratories - a division of ICON plc, (NASDAQ:ICLR) (ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries – today announced the opening of a new laboratory facility in Tianjin, China, in partnership with Fountain Medical Development Ltd (FMD).
BMS today announced that it has signed agreements with ICON and PAREXEL, two leading providers of clinical development services to the biopharmaceutical industry, for joint strategic, operational and capability support of the company’s clinical development program.
ICON plc today announced the launch of the ICOLabs™ Medical Review Application (IMRA) an innovative web based laboratory application that enables more efficient use of medical monitoring time.
today announced the enhancement of its ICOSpeedRead™ system to incorporate RECIST 1.1 evaluation criteria.
ICON today announced that it has acquired Timaq Medical Imaging, a leading European provider of advanced imaging services to pharmaceutical and biotech firms.
First quarter net revenues were $219 million. Income from operations was $26.8 million. Operating margin of 12.2%. Diluted earnings per share increased by 2 cent on last year to 37c. Net new business wins in the quarter of $265m, representing a book-to-bill ratio of 1.2. Dublin, Ireland, April 27, 2010 – ICON (NASDAQ: ICLR) (ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the first quarter ended March 31, 2010. Net revenues for the quart
ICON and Tigermed Consulting, a leader in the provision of clinical drug development services in China, today announced that they have signed an alliance agreement. Through this agreement, ICON and Tigermed will collaborate to offer pharmaceutical and biotechnology clients better access to Chinese patients, utilising the global reach and experience of the ICON organisation, complemented by Tigermed’s in depth knowledge of the Chinese drug development landscape and geographic coverage in China.